Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127168961 | 12716896 | 1 | I | 20160718 | 20160825 | 20160906 | 20160906 | EXP | FR-PFIZER INC-2016403646 | PFIZER | 11.00 | YR | M | Y | 48.00000 | KG | 20160906 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127168961 | 12716896 | 1 | PS | VINCRISTINE SULFATE. | VINCRISTINE SULFATE | 1 | Intravenous (not otherwise specified) | 2 MG (1.5 MG/M2), CYCLIC | Y | 71484 | 2 | MG | |||||||
| 127168961 | 12716896 | 2 | SS | KIDROLASE | ASPARAGINASE | 1 | Intravenous (not otherwise specified) | 1500 IU (1000 IU/M2), CYCLIC | Y | 0 | 1500 | IU | |||||||
| 127168961 | 12716896 | 3 | SS | INEXIUM /01479303/ | ESOMEPRAZOLE | 1 | Oral | 20 MG, 1X/DAY | 300 | MG | Y | 0 | 20 | MG | GASTRO-RESISTANT TABLET | QD | |||
| 127168961 | 12716896 | 4 | SS | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | 1 DF, 3X/ WEEK | Y | 0 | 1 | DF | TABLET | ||||||
| 127168961 | 12716896 | 5 | SS | METHYLPREDNISOLONE MYLAN /00049602/ | METHYLPREDNISOLONE SODIUM SUCCINATE | 1 | Intravenous (not otherwise specified) | 87 MG (60 MG/M2), 1X/DAY | 1305 | MG | Y | 0 | 87 | MG | POWDER FOR SOLUTION FOR INJECTION | QD | |||
| 127168961 | 12716896 | 6 | SS | CERUBIDINE | DAUNORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 44 MG (30 MG/M2), CYCLIC | Y | 0 | 44 | MG | |||||||
| 127168961 | 12716896 | 7 | C | CALCIUM VITAMIN D | CALCIUMVITAMIN D | 1 | UNK | 0 | |||||||||||
| 127168961 | 12716896 | 8 | C | DOLIPRANE | ACETAMINOPHEN | 1 | 0 | ||||||||||||
| 127168961 | 12716896 | 9 | C | SPASFON /00765801/ | PHLOROGLUCINOL1,3,5-TRIMETHOXYBENZENE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127168961 | 12716896 | 1 | Lymphoma |
| 127168961 | 12716896 | 2 | Lymphoma |
| 127168961 | 12716896 | 3 | Gastritis prophylaxis |
| 127168961 | 12716896 | 4 | Infection prophylaxis |
| 127168961 | 12716896 | 5 | Lymphoma |
| 127168961 | 12716896 | 6 | Lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127168961 | 12716896 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127168961 | 12716896 | Gamma-glutamyltransferase increased | |
| 127168961 | 12716896 | Hepatic steatosis | |
| 127168961 | 12716896 | Hepatocellular injury | |
| 127168961 | 12716896 | Hepatomegaly | |
| 127168961 | 12716896 | Jaundice | |
| 127168961 | 12716896 | Splenomegaly |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127168961 | 12716896 | 1 | 20160711 | 20160801 | 0 | |
| 127168961 | 12716896 | 2 | 20160715 | 20160802 | 0 | |
| 127168961 | 12716896 | 3 | 20160704 | 20160805 | 0 | |
| 127168961 | 12716896 | 4 | 20160704 | 20160803 | 0 | |
| 127168961 | 12716896 | 5 | 20160704 | 20160804 | 0 | |
| 127168961 | 12716896 | 6 | 20160711 | 20160801 | 0 | |
| 127168961 | 12716896 | 7 | 20160704 | 0 |